{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:42:53Z","timestamp":1740148973442,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s12325-024-03001-w","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T07:04:41Z","timestamp":1730790281000},"page":"500-509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Retrospective Claims Analysis of the Rate of Complications in Patients Undergoing Treatment for Paroxysmal Nocturnal Hemoglobinuria"],"prefix":"10.1007","volume":"42","author":[{"given":"Denise","family":"Clayton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8444-5979","authenticated-orcid":false,"given":"Jason","family":"Shafrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glorian P.","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lincy","family":"Geevarghese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anem","family":"Waheed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"issue":"1","key":"3001_CR1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bbi.2011.07.239","volume":"26","author":"HH Chang","year":"2012","unstructured":"Chang HH, Lee IH, Gean PW, et al. Treatment response and cognitive impairment in major depression: association with C-reactive protein. Brain Behav Immun. 2012;26(1):90\u20135.","journal-title":"Brain Behav Immun"},{"key":"3001_CR2","unstructured":"Paroxysmal Nocturnal Hemoglobinuria: Cleveland Clinic; 2022 [Available from: https:\/\/my.clevelandclinic.org\/health\/diseases\/22871-paroxysmal-nocturnal-hemoglobinuria#:~:text=This%20condition%20affects%20men%20and,syndrome%20develop%20paroxysmal%20nocturnal%20hemoglobinuria."},{"issue":"2","key":"3001_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1056\/NEJMra2201664","volume":"387","author":"R Notaro","year":"2022","unstructured":"Notaro R, Luzzatto L. Breakthrough hemolysis in PNH with proximal or terminal complement inhibition. N Engl J Med. 2022;387(2):160\u20136.","journal-title":"N Engl J Med"},{"issue":"18","key":"3001_CR4","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","volume":"124","author":"RA Brodsky","year":"2014","unstructured":"Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804\u201311.","journal-title":"Blood"},{"issue":"7","key":"3001_CR5","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00277-020-04052-z","volume":"99","author":"H Schrezenmeier","year":"2020","unstructured":"Schrezenmeier H, Roth A, Araten DJ, et al. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH registry. Ann Hematol. 2020;99(7):1505\u201314.","journal-title":"Ann Hematol"},{"issue":"10","key":"3001_CR6","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00277-017-3059-x","volume":"96","author":"A Villegas","year":"2017","unstructured":"Villegas A, Nunez R, Gaya A, et al. Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH registry. Ann Hematol. 2017;96(10):1727\u201333.","journal-title":"Ann Hematol"},{"key":"3001_CR7","unstructured":"Soliris (eculizumab) [Prescribing Information]: Alexion Pharmaceuticals Inc.; 2020 [Available from: https:\/\/alexion.com\/Documents\/Soliris_USPI.pdf."},{"key":"3001_CR8","unstructured":"Ultomiris (ravulizumab-cwvs) [Prescribing Information]: Alexion Pharmaceuticals Inc.; 2021 [Available from: https:\/\/alexion.com\/documents\/ultomiris_uspi."},{"key":"3001_CR9","unstructured":"Empaveli (pegcetacoplan) [Prescribing Information]. Apellis Pharmaceuticals Inc.; 2021 [Available from: https:\/\/pi.apellis.com\/files\/PI_Empaveli.pdf."},{"key":"3001_CR10","unstructured":"Food and Drug Administration (FDA). FABHALTA\u00ae (iptacopan) Prescribing Information 2024 [updated March 26, 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218276s002lbl.pdf."},{"key":"3001_CR11","unstructured":"Paroxysmal nocturnal hemoglobinuria: National Organization for Rare Disorders; 2021 [Available from: https:\/\/rarediseases.org\/rare-diseases\/paroxysmal-nocturnal-hemoglobinuria."},{"key":"3001_CR12","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3389\/fimmu.2019.01157","volume":"10","author":"AM Risitano","year":"2019","unstructured":"Risitano AM, Marotta S, Ricci P, et al. Anti-complement Treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front Immunol. 2019;10:1157.","journal-title":"Front Immunol"},{"issue":"Supplement_1","key":"3001_CR13","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1182\/blood-2019-125867","volume":"134","author":"JJ Jalbert","year":"2019","unstructured":"Jalbert JJ, Chaudhari U, Zhang H, Weyne J, Shammo JM. Epidemiology of PNH and real-world treatment patterns following an incident PNH diagnosis in the US. Blood. 2019;134(Supplement_1):3407.","journal-title":"Blood"},{"issue":"8","key":"3001_CR14","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.1007\/s12325-021-01825-4","volume":"38","author":"WY Cheng","year":"2021","unstructured":"Cheng WY, Sarda SP, Mody-Patel N, et al. Real-world healthcare resource utilization (HRU) and costs of patients with paroxysmal nocturnal hemoglobinuria (PNH) receiving eculizumab in a US population. Adv Ther. 2021;38(8):4461\u201379.","journal-title":"Adv Ther"},{"key":"3001_CR15","doi-asserted-by":"publisher","first-page":"5830","DOI":"10.1182\/blood-2018-99-113478","volume":"132","author":"MU Yood","year":"2018","unstructured":"Yood MU, Jick S, Vasilakis-Scaramozza C, et al. Baseline characteristics of patients with paroxysmal nocturnal hemoglobinuria identified in the department of defense database. Blood. 2018;132:5830.","journal-title":"Blood"},{"key":"3001_CR16","doi-asserted-by":"publisher","first-page":"107602962312130","DOI":"10.1177\/10760296231213073","volume":"30","author":"D Clayton","year":"2024","unstructured":"Clayton D, Shafrin J, Yen G, et al. Treatment patterns and healthcare resource utilization of patients with paroxysmal nocturnal hemoglobinuria: a retrospective claims data analysis. Clin Appl Thromb Hemost. 2024;30:10760296231213072.","journal-title":"Clin Appl Thromb Hemost"},{"key":"3001_CR17","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00384-014-1972-1","volume":"29","author":"S Marventano","year":"2014","unstructured":"Marventano S, Grosso G, Mistretta A, et al. Evaluation of four comorbidity indices and Charlson comorbidity index adjustment for colorectal cancer patients. Int J Colorectal Dis. 2014;29:1159\u201369.","journal-title":"Int J Colorectal Dis"},{"issue":"1","key":"3001_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjh.12347","volume":"162","author":"P Hillmen","year":"2013","unstructured":"Hillmen P, Muus P, Roth A, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162(1):62\u201373.","journal-title":"Br J Haematol"},{"key":"3001_CR19","doi-asserted-by":"publisher","first-page":"204062072096613","DOI":"10.1177\/2040620720966137","volume":"11","author":"H Schrezenmeier","year":"2020","unstructured":"Schrezenmeier H, Kulasekararaj A, Mitchell L, et al. One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naive to complement inhibitor therapy: open-label extension of a randomized study. Ther Adv Hematol. 2020;11:2040620720966137.","journal-title":"Ther Adv Hematol"},{"key":"3001_CR20","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1182\/blood-2019-125269","volume":"134","author":"K-W Kang","year":"2019","unstructured":"Kang K-W, Moon H, Lee B-H, et al. Real-world efficacy of eculizumab for paroxysmal nocturnal hemoglobinuria in south korea: paradox of eculizumab. Blood. 2019;134:2227.","journal-title":"Blood"},{"key":"3001_CR21","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1182\/blood-2018-99-120139","volume":"132","author":"A Kulagin","year":"2018","unstructured":"Kulagin A, Klimova O, Rudakova T, et al. Benefits and limitations of long-term eculizumab treatment for paroxysmal nocturnal hemoglobinuria (pnh): real-world data from large cohort study in Russia. Blood. 2018;132:2589.","journal-title":"Blood"},{"key":"3001_CR22","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/s12185-011-0867-y","volume":"93","author":"A R\u00f6th","year":"2011","unstructured":"R\u00f6th A, Hock C, Konik A, Christoph S, D\u00fchrsen U. Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena. Int J Hematol. 2011;93:704\u201314.","journal-title":"Int J Hematol"},{"issue":"7","key":"3001_CR23","doi-asserted-by":"publisher","first-page":"E235","DOI":"10.1002\/ajh.26187","volume":"96","author":"A Waheed","year":"2021","unstructured":"Waheed A, Kuter DJ. Iron overload after complement inhibitor treatment of paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2021;96(7):E235\u20137.","journal-title":"Am J Hematol"},{"issue":"4","key":"3001_CR24","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","volume":"111","author":"RA Brodsky","year":"2008","unstructured":"Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840\u20137.","journal-title":"Blood"},{"issue":"6","key":"3001_CR25","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","volume":"133","author":"AG Kulasekararaj","year":"2019","unstructured":"Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133(6):540\u20139.","journal-title":"Blood"},{"key":"3001_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40273-024-01370-2","volume":"42","author":"TS Grand","year":"2024","unstructured":"Grand TS, Ren S, Hall J, \u00c5str\u00f6m DO, Regnier S, Thokala P. Issues, challenges and opportunities for economic evaluations of orphan drugs in rare diseases: an umbrella review. Pharmacoeconomics. 2024;42:1\u201313.","journal-title":"Pharmacoeconomics"},{"key":"3001_CR27","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1002\/jcph.2134","volume":"62","author":"J Liu","year":"2022","unstructured":"Liu J, Barrett JS, Leonardi ET, et al. Natural history and real-world data in rare diseases: applications, limitations, and future perspectives. J Clin Pharmacol. 2022;62:S38\u201355.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"3001_CR28","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ejvs.2018.06.001","volume":"56","author":"C-A Behrendt","year":"2018","unstructured":"Behrendt C-A, Debus ES, Mani K, Sedrakyan A. The strengths and limitations of claims based research in countries with fee for service reimbursement. Eur J Vasc Endovasc Surg. 2018;56(5):615\u20136.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"4","key":"3001_CR29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/1062860606288243","volume":"21","author":"LI Solberg","year":"2006","unstructured":"Solberg LI, Engebretson KI, Sperl-Hillen JM, Hroscikoski MC, O\u2019Connor PJ. Are claims data accurate enough to identify patients for performance measures or quality improvement? The case of diabetes, heart disease, and depression. Am J Med Qual. 2006;21(4):238\u201345.","journal-title":"Am J Med Qual"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03001-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03001-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03001-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T11:02:41Z","timestamp":1738234961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03001-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3001"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03001-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Denise Clayton is an employee of SSR Health, but was an employee of FTI Consulting during the time this study was conducted. FTI Consulting received funding from Novartis Pharmaceuticals Corporation, Inc. Jason Shafrin is employed by FTI Consulting, which received funding from Novartis Pharmaceuticals Corporation, Inc. Glorian P.\u00a0Yen is employed by Novartis Pharmaceuticals Corporation, Inc. Lincy Geevarghese is employed by Novartis Pharmaceuticals Corporation, Inc. Yulin Shi is employed by KMK Consulting Inc. and receives funding from Novartis Pharmaceuticals Corporation, Inc. Anem Waheed consults for Novartis Pharmaceuticals Corporation, Inc, and receives funding from Novartis Pharmaceuticals Corporation, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"MarketScan data are de-identified and comply with the confidentiality requirements of the HIPAA. MarketScan data are collected as part of billing for routine patient care and deidentified before access is granted to researchers; therefore no Institutional Review Board review or patient consent was needed. The Observational Study was performed in accordance with the regulations and guidelines governing medical practice and ethics in the country of the Observational Study and in accordance with the Helsinki Declaration of 1964 and its later amendments, with currently acceptable techniques and know-how. Permission was obtained by all authors to access the MarketScan data used in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}